Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan
Abstract Background Maintaining the connection between skeletal muscle fibers and the surrounding basement membrane is essential for muscle function. Dystroglycan (DG) serves as a basement membrane extracellular matrix (ECM) receptor in many cells, and is also expressed in the outward-facing membran...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Skeletal Muscle |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13395-024-00370-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544185462652928 |
|---|---|
| author | Jeffrey M. Hord Sarah Burns Tobias Willer Matthew M. Goddeeris David Venzke Kevin P. Campbell |
| author_facet | Jeffrey M. Hord Sarah Burns Tobias Willer Matthew M. Goddeeris David Venzke Kevin P. Campbell |
| author_sort | Jeffrey M. Hord |
| collection | DOAJ |
| description | Abstract Background Maintaining the connection between skeletal muscle fibers and the surrounding basement membrane is essential for muscle function. Dystroglycan (DG) serves as a basement membrane extracellular matrix (ECM) receptor in many cells, and is also expressed in the outward-facing membrane, or sarcolemma, of skeletal muscle fibers. DG is a transmembrane protein comprised of two subunits: alpha-DG (α-DG), which resides in the peripheral membrane, and beta-DG (β-DG), which spans the membrane to intracellular regions. Extensive post-translational processing and O-mannosylation are required for α-DG to bind ECM proteins, which is mediated by a glycan structure known as matriglycan. O-mannose glycan biosynthesis is initiated by the protein O-mannosyltransferase 1 (POMT1) and POMT2 enzyme complex and leads to three subtypes of glycans called core M1, M2, and M3. The lengthy core M3 is capped with matriglycan. Genetic defects in post-translational O-mannosylation of DG interfere with its receptor function and result in muscular dystrophy with central nervous system and skeletal muscle pathophysiology. Methods To evaluate how the loss of O-mannosylated DG in skeletal muscle affects the development and progression of myopathology, we generated and characterized mice in which the Pomt1 gene was specifically deleted in skeletal muscle (Pomt1skm) to interfere with POMT1/2 enzyme activity. To investigate whether matriglycan is the primary core M glycan structure that provides the stabilizing link between the sarcolemma and ECM, we generated mice that retained cores M1, M2, and M3, but lacked matriglycan (conditional deletion of like-acetylglucosaminyltransferase 1; Large1skm). Next, we restored Pomt1 using gene transfer via AAV2/9-MCK-mPOMT1 and determined the effect on Pomt1skm pathophysiology. Results Our data showed that in Pomt1skm mice O-mannosylated DG is required for sarcolemma resilience, remodeling of muscle fibers and muscle tissue, and neuromuscular function. Notably, we observed similar body size limitations, sarcolemma weakness, and neuromuscular weakness in Large1skm mice that only lacked matriglycan. Furthermore, our data indicate that genetic rescue of Pomt1 in Pomt1skm mice limits contraction-induced sarcolemma damage and skeletal muscle pathology. Conclusions Collectively, our data indicate that DG modification by Pomt1/2 results in core M3 capped with matriglycan, and that this is required to reinforce the sarcolemma and enable skeletal muscle health and neuromuscular strength. |
| format | Article |
| id | doaj-art-20f53da2021c4c7c8c212fc8b68433b9 |
| institution | Kabale University |
| issn | 2044-5040 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Skeletal Muscle |
| spelling | doaj-art-20f53da2021c4c7c8c212fc8b68433b92025-01-12T12:45:02ZengBMCSkeletal Muscle2044-50402025-01-0115111710.1186/s13395-024-00370-2Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycanJeffrey M. Hord0Sarah Burns1Tobias Willer2Matthew M. Goddeeris3David Venzke4Kevin P. Campbell5Department of Molecular Physiology and Biophysics, and Department of Neurology, Howard Hughes Medical Institute, Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, Roy J. and Lucille A. Carver College of Medicine, The University of IowaDepartment of Molecular Physiology and Biophysics, and Department of Neurology, Howard Hughes Medical Institute, Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, Roy J. and Lucille A. Carver College of Medicine, The University of IowaDepartment of Molecular Physiology and Biophysics, and Department of Neurology, Howard Hughes Medical Institute, Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, Roy J. and Lucille A. Carver College of Medicine, The University of IowaDepartment of Molecular Physiology and Biophysics, and Department of Neurology, Howard Hughes Medical Institute, Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, Roy J. and Lucille A. Carver College of Medicine, The University of IowaDepartment of Molecular Physiology and Biophysics, and Department of Neurology, Howard Hughes Medical Institute, Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, Roy J. and Lucille A. Carver College of Medicine, The University of IowaDepartment of Molecular Physiology and Biophysics, and Department of Neurology, Howard Hughes Medical Institute, Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Center, Roy J. and Lucille A. Carver College of Medicine, The University of IowaAbstract Background Maintaining the connection between skeletal muscle fibers and the surrounding basement membrane is essential for muscle function. Dystroglycan (DG) serves as a basement membrane extracellular matrix (ECM) receptor in many cells, and is also expressed in the outward-facing membrane, or sarcolemma, of skeletal muscle fibers. DG is a transmembrane protein comprised of two subunits: alpha-DG (α-DG), which resides in the peripheral membrane, and beta-DG (β-DG), which spans the membrane to intracellular regions. Extensive post-translational processing and O-mannosylation are required for α-DG to bind ECM proteins, which is mediated by a glycan structure known as matriglycan. O-mannose glycan biosynthesis is initiated by the protein O-mannosyltransferase 1 (POMT1) and POMT2 enzyme complex and leads to three subtypes of glycans called core M1, M2, and M3. The lengthy core M3 is capped with matriglycan. Genetic defects in post-translational O-mannosylation of DG interfere with its receptor function and result in muscular dystrophy with central nervous system and skeletal muscle pathophysiology. Methods To evaluate how the loss of O-mannosylated DG in skeletal muscle affects the development and progression of myopathology, we generated and characterized mice in which the Pomt1 gene was specifically deleted in skeletal muscle (Pomt1skm) to interfere with POMT1/2 enzyme activity. To investigate whether matriglycan is the primary core M glycan structure that provides the stabilizing link between the sarcolemma and ECM, we generated mice that retained cores M1, M2, and M3, but lacked matriglycan (conditional deletion of like-acetylglucosaminyltransferase 1; Large1skm). Next, we restored Pomt1 using gene transfer via AAV2/9-MCK-mPOMT1 and determined the effect on Pomt1skm pathophysiology. Results Our data showed that in Pomt1skm mice O-mannosylated DG is required for sarcolemma resilience, remodeling of muscle fibers and muscle tissue, and neuromuscular function. Notably, we observed similar body size limitations, sarcolemma weakness, and neuromuscular weakness in Large1skm mice that only lacked matriglycan. Furthermore, our data indicate that genetic rescue of Pomt1 in Pomt1skm mice limits contraction-induced sarcolemma damage and skeletal muscle pathology. Conclusions Collectively, our data indicate that DG modification by Pomt1/2 results in core M3 capped with matriglycan, and that this is required to reinforce the sarcolemma and enable skeletal muscle health and neuromuscular strength.https://doi.org/10.1186/s13395-024-00370-2DystroglycanO-mannosylationProtein O-mannosyltransferase 1 (POMT1)Like-acetylglucosaminyltransferase 1 (LARGE1)MatriglycanSkeletal muscle |
| spellingShingle | Jeffrey M. Hord Sarah Burns Tobias Willer Matthew M. Goddeeris David Venzke Kevin P. Campbell Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan Skeletal Muscle Dystroglycan O-mannosylation Protein O-mannosyltransferase 1 (POMT1) Like-acetylglucosaminyltransferase 1 (LARGE1) Matriglycan Skeletal muscle |
| title | Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan |
| title_full | Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan |
| title_fullStr | Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan |
| title_full_unstemmed | Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan |
| title_short | Sarcolemma resilience and skeletal muscle health require O-mannosylation of dystroglycan |
| title_sort | sarcolemma resilience and skeletal muscle health require o mannosylation of dystroglycan |
| topic | Dystroglycan O-mannosylation Protein O-mannosyltransferase 1 (POMT1) Like-acetylglucosaminyltransferase 1 (LARGE1) Matriglycan Skeletal muscle |
| url | https://doi.org/10.1186/s13395-024-00370-2 |
| work_keys_str_mv | AT jeffreymhord sarcolemmaresilienceandskeletalmusclehealthrequireomannosylationofdystroglycan AT sarahburns sarcolemmaresilienceandskeletalmusclehealthrequireomannosylationofdystroglycan AT tobiaswiller sarcolemmaresilienceandskeletalmusclehealthrequireomannosylationofdystroglycan AT matthewmgoddeeris sarcolemmaresilienceandskeletalmusclehealthrequireomannosylationofdystroglycan AT davidvenzke sarcolemmaresilienceandskeletalmusclehealthrequireomannosylationofdystroglycan AT kevinpcampbell sarcolemmaresilienceandskeletalmusclehealthrequireomannosylationofdystroglycan |